Halozyme Therapeutics Sees FY24 EPS $3.65-$4.05 Vs $3.99 Est.; Revenue $935M-$1.015B Vs $989.87M Est.
Portfolio Pulse from Benzinga Newsdesk
Halozyme Therapeutics has reiterated its financial guidance for 2024, projecting EPS of $3.65-$4.05 and revenue of $935M-$1.015B. This represents significant growth over 2023, driven by increases in royalty revenue, collaboration revenue, and product sales from XYOSTED®. Adjusted EBITDA is expected to grow by 30% to 44%.
August 06, 2024 | 8:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Halozyme Therapeutics has reiterated its financial guidance for 2024, projecting EPS of $3.65-$4.05 and revenue of $935M-$1.015B. This represents significant growth over 2023, driven by increases in royalty revenue, collaboration revenue, and product sales from XYOSTED®. Adjusted EBITDA is expected to grow by 30% to 44%.
The reaffirmation of strong financial guidance for 2024, including significant growth in EPS, revenue, and adjusted EBITDA, is likely to positively impact Halozyme Therapeutics' stock price in the short term. Investors are likely to respond favorably to the projected growth driven by increases in royalty revenue, collaboration revenue, and product sales from XYOSTED®.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100